Participation in All Three Major Global Oncology Conferences This Year

On July 30, SillaJen announced that the results of its Phase 1 clinical study of its next-generation anti-cancer pipeline 'BAL0891' have been selected for poster presentation at the European Society for Medical Oncology (ESMO 2026).

SillaJen's 'BAL0891' Selected for Poster Presentation at ESMO 2026 View original image

ESMO is considered one of the top three global oncology societies, alongside the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). The event is scheduled to be held in Madrid, Spain from October 23 to 27, local time.


With this acceptance by ESMO, SillaJen has achieved the milestone of participating in all three of the world's leading oncology conferences this year. This provides an opportunity to demonstrate the technology and significant clinical achievements of BAL0891 to the global market from multiple perspectives.


Notably, at the end of May, SillaJen released initial clinical data of BAL0891 at the annual meeting of the American Society of Clinical Oncology (ASCO 2026), drawing attention from the academic community with successful results such as the identification of the recommended Phase 2 dose (RP2D).


Building on these achievements, SillaJen plans to present Phase 1 research results on the safety and efficacy of BAL0891 monotherapy, as well as a combination therapy with paclitaxel, in patients with advanced solid tumors at ESMO.


A SillaJen representative stated, "BAL0891 is gaining recognition for its technological capabilities as we participate in all three major global oncology conferences this year," adding, "We will do our best to share meaningful research outcomes at ESMO as well."



Meanwhile, SillaJen is currently conducting Phase 1 clinical trials of BAL0891 in four separate cohorts for patients with solid tumors and acute myeloid leukemia (AML) at major clinical centers in the United States and Korea.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing